Intersect ENT story remains interesting even without J-Code, says Piper Jaffray

Piper Jaffray analyst Matt O’Brien noted that Intersect ENT management said along with the company’s Q3 report that SINUVA is most likely not going to receive a product-specific J-code for 2019, which he said is in contrast to previous messaging. However, he believes the code is not necessary, but would have provided upside, to the SINUVA ramp. O’Brien still believes the Intersect ENT story remains interesting and keeps an Overweight rating on the shares, which are down 3% to $27.98 in afternoon trading.
https://thefly.com/landingPageNews.php?id=2817659